佐力藥業(300181.SZ):擬371.27萬元收購佐力百草醫藥剩餘20%股權
格隆匯12月15日丨佐力藥業(300181.SZ)宣佈,基於公司發展中藥飲片和中藥配方顆粒的整體發展戰略規劃,為有利於公司支持佐力百草醫藥做大經營規模,公司擬通過協議轉讓的方式收購佐力百草醫藥少數股東合計持有佐力百草醫藥20%的股權,簡化股權結構。
公司擬以人民幣185.6359萬元收購關聯自然人股東沈愛瑛所持佐力百草醫藥10%的股權;擬以人民幣185.6359萬元收購非關聯自然人股東黃明偉10%的股權。該次交易完成後,佐力百草醫藥將成為公司全資子公司,公司持有其100%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.